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INRA, Human Nutrition Division, Rennes and Human Nutrition Research Centre-West, Nantes, FranceThe epidemic of metabolic disorders, including insulin resistance, should be taken in evaluating an individual value in the context of con-
type 2 diabetes mellitus (T2DM) and obesity is observed in both devel-
oped and developing countries. It now affects all age categories and is
often associated in the context of low physical activity with chronic in-
take of unbalanced (Western) diets characterized by high fat, sugars
and low ﬁber. Western diets are invariably related to gut dysbiosis (e.g.
as in obesity), and a higher intestinal translocation of pro-inﬂammatory
microbial components like lipopolysaccharide into the systemic circula-
tion is promoted, thus leading to chronic low-grade systemic inﬂamma-
tion and metabolic shifts towards higher body fat accumulation that
ultimately results in the metabolic syndrome and diabetes.
Many data indicate that intestinal alkaline phosphatase (IAP), an en-
zyme isoformuniquely secreted by enterocytes, consistently reduces in-
ﬂammation in animal models and in diseases (e.g. in ulcerative colitis,
peritonitis, sepsis and heart surgery) inman (Lallès, 2014).Malo and co-
workers at Harvard University have previously demonstrated that en-
dogenous, as well as exogenous (bovine) IAP taken orally can prevent,
and treat, fat-diet induced metabolic syndrome and T2DM in mice
(Kaliannan et al., 2013). This group has also published other decisive pa-
pers showing intimate cross-regulation between the gutmicrobiota and
IAP in mice, clearly revealing this enzyme as a potent regulator of in-
ﬂammation and gut microbiota homeostasis (Lallès, 2014). Data on
IAP are scant in humans. In a paper recently published in EBioMedicine,
Malo now reports for theﬁrst time that fecal IAP (fIAP) and T2DMstatus
were independently and negatively associated, both inmale and female
adults, in a T2DM case–control study conducted in Bangladesh (Malo,
2015). Even more importantly, Malo noted that fIAP was low in 65% of
control subjects and suggested fIAP as a possible biomarker for “incipi-
ent metabolic syndrome” including “incipient diabetes” in healthy sub-
jects (Malo, 2015). Collectively, these new data perfectly ﬁt with all that
is now known on IAP and inﬂammation (Lallès, 2014). IAP is speciﬁcally
inhibited by L-phenylalanine allowing it to be distinguished frommicro-
bial AP. fIAP and microbial AP account for 80 and 20%, respectively of
total stool AP activity in humans and for 60 and 40% in rodents (Malo,
2015; Kim et al., 1986). IAP oral administration was shown to increase
fIAP dose-dependently in mice (Lallès, 2014).
This new study by Malo is potentially important as it proposes fIAP
as a biomarker of T2DM (and metabolic diseases). However, cautionE-mail address: Jean-Paul.Lalles@rennes.inra.fr.
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marker of intestinal epithelial damage (Thomas & Henton, 1985). In ad-
dition, changes in food intake per se could explain most of the effects
assigned to other factors, and indeed, enteral feeding is recognized as
a major driver of intestinal production and fecal release of IAP (Lallès,
2014; Thomas & Henton, 1985). Further, many dietary components
(e.g. fat, the anti-inﬂammatory spice curcumin and minerals), and also
antibiotics and other drugs (e.g. protease inhibitors), alcohol and laxa-
tives are known to modulate fIAP (Lallès, 2014; Ghosh et al., 2014;
Davis, 2003; Wu et al., 2010; Hufnagel et al., 1980; Taché et al., 2006).
Thus, in the case of an individual, fIAP data needs to be interpreted in
light of these dietary factors and treatments.
In conclusion, these data by Malo showing an association between
fIAP and T2DM, and also suggesting “incipient T2DM” in (apparently)
healthy subjects based on fIAP values, are very interesting. However,
any individual IAP value should be evaluated in the context of associat-
ed factors modulating fIAP.
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